I am encouraged that Botanix said that 50% of dermatologists...

I am encouraged that Botanix said that 50% of dermatologists they spoke with would try Sofdra as first line, and they plan on having a big sales force visiting those 4500 dermatologists.

Their sales and market penetration plan, looks very aggressive, and I don't know if Kaken have taken steps anything like what BOT are proposing.

Of interest, 85% of patients for the BOT trial said they felt an improvement, whereas only around 65% from qbrexa trial ( current best approved treatment ) said they felt improvement. The gravametric sweat reduction was similar at close to 70% for the two products. Price is 600 to 700 per month for qbrexa.

So while not 100%, according to the patients, 85% vs 65%, its a better product than the only FDA approved treatment currently available , and will be at a similar price.